Randomized Trialvery high evidence
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
The New England journal of medicine·June 5, 2025·PMID 40305708
Why it mattersMASH with stage 2-3 fibrosis has limited effective medical therapy and high risk of progression. This trial provides high-level evidence that semaglutide can improve liver histology in addition to weight, making it a relevant option for patients with metabolic disease and biopsy-proven fibrotic MASH.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled